Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.46 |
| ▸ | UMPS | P11172 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28783554 | 0.84 | SLC5A2 (0.47) | SLC5A2UMPSSLC5A1 | |
| SCHEMBL29602777 | 0.84 | SLC5A2 (0.47) | SLC5A2UMPSSLC5A1 | |
| SCHEMBL27588394 | 0.81 | UMPS (0.44) | SLC5A2UMPSPYGL | |
| SCHEMBL27606205 | 0.81 | UMPS (0.44) | SLC5A2UMPSPYGL | |
| SCHEMBL6784339 | 0.81 | UMPS (0.44) | SLC5A2UMPSPYGL | |
| SCHEMBL5878336 | 0.81 | UMPS (0.44) | SLC5A2UMPSPYGL | |
| SCHEMBL6790961 | 0.81 | UMPS (0.44) | SLC5A2UMPSPYGL | |
| SCHEMBL14590154 | 0.78 | SLC5A2 (0.71) | SLC5A2SLC5A1 | |
| SCHEMBL15284586 | 0.78 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL15284566 | 0.76 | SLC5A2 (0.59) | SLC5A2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMA (US) | 2022-05-05 | — | — | US | disclosed |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-11 | — | — | US | disclosed |
| US-9963478-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-08 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | DHPS, CFTR, FDPS | SLC5A2 2191/4885UMPS 324/4885SLC5A1 2475/4885 |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885UMPS 120/4885SLC5A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.